Clinical Trial Update: Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating TKI258 (pacritinib? or unknown) in FGFR1 amplified and non-amplified metastatic HER2-negative breast cancer assessing safety and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• TKI258

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED